(ISRG) Intuitive Surgical - NASDAQ
Sector: Healthcare | Industry: Medical Instruments & Supplies | Exchange: NASDAQ (USA) | Market Cap: 142.313m USD | Total Return: -24.2% in 12m
Avg Turnover: 1.05B
EPS Trend: 99.6%
Qual. Beats: 4
Rev. Trend: 99.6%
Qual. Beats: 7
Warnings
Fakeout Below Avwap Earnings
Tailwinds
No distinct edge detected
Intuitive Surgical, Inc. (NASDAQ: ISRG) develops and markets technologies that enable minimally invasive care, anchored by its flagship da Vinci Surgical System, a robotic-assisted platform used in surgical procedures. The company has extended its portfolio with the Ion endoluminal system, which supports minimally invasive lung biopsies, moving beyond the operating room into diagnostic procedures.
The business model combines capital equipment sales of surgical systems with a recurring revenue stream from disposable instruments, energy devices, and stapling products used in each procedure, supplemented by installation, maintenance, 24/7 technical support, and digital program-management services. Products are sold through direct capital and clinical sales teams, and the company maintains a deep customer-service and training infrastructure. As a medical-device manufacturer, ISRG operates in a sector characterized by long product cycles, significant regulatory oversight, and high switching costs once a hospital system is integrated into a platform.
Intuitive Surgical was incorporated in 1995, is headquartered in Sunnyvale, California, and trades as a large-cap stock in the Health Care Equipment sub-industry, having gone public in 2000.
- Da Vinci procedure volume drives recurring instrument and accessory revenue
- Ion endoluminal system adoption accelerates diagnostic lung biopsy growth
- Medtronic Hugo and J&J Ottava intensify robotic surgery competition
- Hospital capital budget cycles pressure new system placements
| Net Income: 2.98b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.14 > 0.02 and ΔFCF/TA 5.01 > 1.0 |
| NWC/Revenue: 90.80% < 20% (prev 70.22%; Δ 20.58% < -1%) |
| CFO/TA 0.17 > 3% & CFO 3.36b > Net Income 2.98b |
| Net Debt (-4.16b) to EBITDA (4.32b): -0.96 < 3 |
| Current Ratio: 6.03 > 1.5 & < 3 |
| Outstanding Shares: last quarter (359.8m) vs 12m ago -1.32% < -2% |
| Gross Margin: 66.29% > 18% (prev 67.09%; Δ -0.79% > 0.5%) |
| Asset Turnover: 53.81% > 50% (prev 45.34%; Δ 8.47% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.48 (Total Current Assets 11.5b - Total Current Liabilities 1.91b) / Total Assets 20.1b |
| B: 0.32 (Retained Earnings 6.40b / Total Assets 20.1b) |
| C: 0.18 (EBIT TTM 3.58b / Avg Total Assets 19.7b) |
| D: 6.95 (Book Value of Equity 17.5b / Total Liabilities 2.51b) |
| Altman-Z'' = 12.69 = AAA |
| DSRI: 1.04 (Receivables 1.71b/1.35b, Revenue 10.6b/8.71b) |
| GMI: 1.01 (GM 67.09% / 66.29%) |
| AQI: 0.44 (AQ_t 0.16 / AQ_t-1 0.35) |
| SGI: 1.21 (Revenue 10.6b / 8.71b) |
| TATA: -0.02 (NI 2.98b - CFO 3.36b) / TA 20.1b) |
| Beneish M = -3.16 (Cap -4..+1) = AA |
As of June 28, 2026, the stock is trading at USD 404.70 with a total of 3,370,282 shares traded. Over the past week, the price has changed by -0.51%, over one month by -7.31%, over three months by -13.63% and over the past year by -24.24%.
Current recommended Stop Loss: 389.80 (which is 3.7% or 1.2 ATR below the current price).
Intuitive Surgical has received a consensus analysts rating of 4.03. Therefore, it is recommended to buy ISRG.
- StrongBuy: 14
- Buy: 8
- Hold: 10
- Sell: 0
- StrongSell: 1
| Analysts Target Price | 565.1 | 39.6% |
P/E Trailing = 48.7658
P/E Forward = 38.7597
P/S = 13.4485
P/B = 8.1441
P/EG = 2.107
Revenue TTM = 10.6b USD
EBIT TTM = 3.58b USD
EBITDA TTM = 4.32b USD
Long Term Debt = unknown (none)
Short Term Debt = 39.0m USD (from shortTermDebt, last fiscal year)
Debt = 389.8m USD (from shortLongTermDebtTotal, last fiscal year) + Leases 87.0m
Net Debt = -4.16b USD (calculated: Debt 389.8m - CCE 4.55b)
Enterprise Value = 138b USD (142b + Debt 389.8m - CCE 4.55b)
Interest Coverage Ratio = unknown (Ebit TTM 3.58b / Interest Expense TTM 0.0)
EV/FCF = 48.74x (Enterprise Value 138b / FCF TTM 2.83b)
FCF Yield = 2.05% (FCF TTM 2.83b / Enterprise Value 138b)
FCF Margin = 26.78% (FCF TTM 2.83b / Revenue TTM 10.6b)
Net Margin = 28.15% (Net Income TTM 2.98b / Revenue TTM 10.6b)
Gross Margin = 66.29% ((Revenue TTM 10.6b - Cost of Revenue TTM 3.57b) / Revenue TTM)
Gross Margin QoQ = 66.06% (prev 66.44%)
Tobins Q-Ratio = 6.87 (Enterprise Value 138b / Total Assets 20.1b)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 389.8m)
Taxrate = 16.31% (584.4m / 3.58b)
NOPAT = 3.00b (EBIT 3.58b * (1 - 16.31%))
Current Ratio = 6.03 (Total Current Assets 11.5b / Total Current Liabilities 1.91b)
Debt / Equity = 0.02 (Debt 389.8m / totalStockholderEquity, last quarter 17.5b)
Debt / EBITDA = -0.96 (Net Debt -4.16b / EBITDA 4.32b)
Debt / FCF = -1.47 (Net Debt -4.16b / FCF TTM 2.83b)
Total Stockholder Equity = 17.5b (last 4 quarters mean from totalStockholderEquity)
RoA = 15.15% (Net Income 2.98b / Total Assets 20.1b)
RoE = 17.01% (Net Income TTM 2.98b / Total Stockholder Equity 17.5b)
RoCE = 19.69% (EBIT 3.58b / Capital Employed (Total Assets 20.1b - Current Liab 1.91b))
RoIC = 16.93% (NOPAT 3.00b / Invested Capital 17.7b)
WACC = 8.59% (E(142b)/V(143b) * Re(8.61%) + D(389.8m)/V(143b) * Rd(0.0%) * (1-Tc(0.16)))
Discount Rate = 8.61% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 11.11 | Cagr: 0.20%
[DCF] Terminal Value 77.21% ; FCFF base≈2.40b ; Y1≈2.75b ; Y5≈4.05b
[DCF] Fair Price = 176.8 (EV 58.5b - Net Debt -4.16b = Equity 62.6b / Shares 354.2m; r=8.59% [WACC]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 99.58 | EPS CAGR: 23.84% | SUE: 3.03 | # QB: 4
Revenue Correlation: 99.58 | Revenue CAGR: 18.67% | SUE: 2.86 | # QB: 7
EPS current Quarter (2026-06-30): EPS=2.50 | Chg30d=+0.01% | Revisions=+20% | Analysts=24
EPS next Quarter (2026-09-30): EPS=2.59 | Chg30d=+0.19% | Revisions=+20% | Analysts=24
EPS current Year (2026-12-31): EPS=10.42 | Chg30d=+0.08% | Revisions=+20% | GrowthEPS=+16.7% | GrowthRev=+16.3%
EPS next Year (2027-12-31): EPS=11.79 | Chg30d=-0.03% | Revisions=+0% | GrowthEPS=+13.1% | GrowthRev=+13.2%
[Analyst] Revisions Ratio: +20%